Cagri Savran, Founder - Biotech Angel Bootcamp I

<p>Join Sal's Syndicate: https://www.angelinvestboston.com/our-syndicates</p> <p>Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson</p> <p>Hesitant about investing in biotech startups? Founder Çağrı Savran and I discuss the unique opportunities and requirements of angel-scale life science startups. This is the first in a series of biotech angel bootcamps.</p> <p>Highlights:</p> <ul> <li>Podcast Sponsored by Purdue University Entrepreneurship and Peter Fasse, Patent Attorney</li> <li>Sal Daher Introduces Founder, Çağrı Savran, PhD</li> <li>Purdue University Now Evaluates Professors of Engineering on Translation of their Technology to Industry as Well as on Publications and Citations</li> <li>Episode Created for Angel Investors Who Are Hesitant About Biotech</li> <li>Savran’s First Round of Funding Was Very Easy, the Subsequent Three Rounds Took Great Effort</li> <li>Several Walnut Members Had Invested in SQZ, Which Also Had a Fast Angel Round</li> <li>“...they saw parallels between SQZ and Savran.”</li> <li>” If somebody is taking too much time to think, they're probably not interested and that's okay. You don't need the whole world...”</li> <li>“...it's similar to marriage... Sometimes it clicks, sometimes it doesn't click.”</li> <li>There Are Many People Looking for Attractive Investment Alternatives – It’s About Finding Those People</li> <li>Sal Asks About an Alternative Way to Fund Biotech Startups that Could Be More Efficient in the Long Run</li> <li>Angels Should Consider Staging their Investment in Biotech Startups Over Four Years with Annual Drawdown Based on Milestones</li> <li>Staged Funding Would Provide a Stable Financing Path So Founders Can Focus on the Business</li> <li>Angel Investors Have Contributed Much More than Money to Savran Tech; Advice, Introductions and Encouragement</li> <li>Çağrı Savran Wants Angels to Appreciate All the Trial & Error Involved in Building Life Science Companies</li> <li>When Things Work Out, Life Science Companies Can B